Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.62 |
| ▸ | CTSL | P07711 | 3/20 | 0.59 |
| ▸ | CTSS | P25774 | 3/20 | 0.59 |
| ▸ | CTSK | P43235 | 3/20 | 0.59 |
| ▸ | CTSH | P09668 | 1/20 | 0.59 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.54 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.51 |
| ▸ | APLNR | P35414 | 1/20 | 0.51 |
| ▸ | DPP3 | Q9NY33 | 4/20 | 0.49 |
| ▸ | MC4R | P32245 | 2/20 | 0.48 |
| ▸ | MC5R | P33032 | 2/20 | 0.48 |
| ▸ | MC3R | P41968 | 2/20 | 0.48 |
| ▸ | MC1R | Q01726 | 2/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5405514 | 1.00 | C5AR1 (0.62) | C5AR1CTSLCTSSCTSKCTSH | |
| SCHEMBL30609016 | 0.92 | CTSL (0.60) | C5AR1CTSLCTSSCTSKCTSH | |
| SCHEMBL30609010 | 0.92 | CTSL (0.60) | C5AR1CTSLCTSSCTSKCTSH | |
| SCHEMBL30183179 | 0.89 | CTSL (0.58) | C5AR1CTSLCTSSCTSKCTSH | |
| SCHEMBL31040596 | 0.89 | CTSL (0.59) | C5AR1CTSLCTSSCTSKCTSH | |
| SCHEMBL30609005 | 0.88 | CTSL (0.61) | C5AR1CTSLCTSSCTSKCTSH | |
| SCHEMBL30577311 | 0.88 | CTSL (0.61) | C5AR1CTSLCTSSCTSKCTSH | |
| SCHEMBL34461111 | 0.88 | DPP3 (0.56) | C5AR1CTSLCTSSCTSKCTSH | |
| SCHEMBL34461092 | 0.88 | CXCR4 (0.59) | C5AR1CXCR4KISS1RDPP3 | |
| SCHEMBL30301165 | 0.88 | C5AR1 (0.67) | C5AR1CTSLCTSSCTSKCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279170-B2 | 32-kDa protein derived from Mycobacterium tuberculosis and related peptides | N.V. INNOGENETICS S.A. (BE) | 2007-10-09 | — | — | US | disclosed |
| US-20070003569-A1 | 32-kDa protein derived from Mycobacterium tuberculosis and related peptides | N.V. INNOGENETICS S.A. (BE) | 2007-01-04 | — | — | US | disclosed |
| US-7083797-B2 | 32-kDa protein derived from Mycobacterium tuberculosis and related peptides | N.V. INNOGENETICS S.A. (BE) | 2006-08-01 | — | — | US | disclosed |
| US-20030225249-A1 | 32-kDa protein derived from mycobacterium tuberculosis and related peptides | N.V. INNOGENETICS S.A., A BELGIUM CORPORATION | 2003-12-04 | — | — | US | disclosed |
| US-6531138-B1 | Conjugated polypeptide composition induces the production of antibodies against Mycobacterium tuberculosis | N.V. INNOGENETICS S.A. (BE) | 2003-03-11 | — | — | US | disclosed |
| EP-0419355-B1 | Recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnostic of tuberculosis | INNOGENETICS NV (BE) | 2000-02-09 | — | — | EP | disclosed |
| US-5916558-A | Recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnostic of tuberculosis | N.V. INNOGENETICS S.A. (BE) | 1999-06-29 | — | — | US | disclosed |
| WO-1991004272-A1 | RECOMBINANT POLYPEPTIDES AND PEPTIDES, NUCLEIC ACIDS CODING FOR THE SAME AND USE OF THESE POLYPEPTIDES AND PEPTIDES IN THE DIAGNOSTIC OF TUBERCULOSIS | N.V. INNOGENETICS S.A. (BE) | 1991-04-04 | — | — | WO | disclosed |
| EP-0419355-A1 | Recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnostic of tuberculosis | N.V. INNOGENETICS S.A. (BE) | 1991-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225249-A1 | 32-kDa protein derived from mycobacterium tuberculosis and related peptides | PA2G4, EPB41L2, SPPL2B | C5AR1 1608/4885CTSL 1731/4885CTSS 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.